$DMRA News

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Therapeutics: Competition Validates The Target While Its Portfolio Creates The Upside

Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Damora Therapeutics Q2 EPS $(0.39) Beats $(0.43) Estimate

Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis

Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Study Of DMR-001 To Treat Patients With Mutcalr-Driven Essential Thrombocythemia And Myelofibrosis

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wedbush Maintains Outperform on Damora Therapeutics, Raises Price Target to $40

Jefferies Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Target of $50

HC Wainwright & Co. Reiterates Buy on Damora Therapeutics, Maintains $45 Price Target

Damora Announces Redomestication from Delaware to Cayman Islands

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $35 Price Target

HC Wainwright & Co. Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Target of $45

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wedbush Initiates Coverage On Damora Therapeutics with Outperform Rating, Announces Price Target of $35

Damora Therapeutics: Well-Funded Moonshot For CALR Mutations

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Damora Therapeutics Says On Track For First Regulatory Submission For DMR-001 In Mid-2026

Damora Therapeutics Q1 EPS $(0.62) Misses $(0.40) Estimate